The Effects of Anti-vascular Endothelial Growth Factor Agents on Human Retinal Pigment Epithelial Cells Under High Glucose Conditions

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2017 Mar 3

PMID 28251077

Citations 4

Authors

Jong Rok Oh

Jung Woo Han

Yoon Kyung Kim

Young-Hoon Ohn

Tae Kwann Park

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effects of high glucose levels and anti-vascular endothelial growth factor (VEGF) agents (bevacizumab, ranibizumab and aflibercept) on retinal pigment epithelium (RPE) cells.

Methods: ARPE-19 cells were cultured at different glucose levels (5.5 mmol/L, 25 mmol/L, and 75 mmol/L). Cell viability was evaluated by MTT assay at 3d after treatment with D-glucose. Cell migration ability was measured by wound healing assay at 3d. A cell death detection kit was used to assess apoptosis at 3 and 14d. Cell proliferation was assessed by EdU assay at 3d. The culture medium was treated with anti-VEGF agents at clinically relevant concentrations. The experiment was then repeated at a different glucose level.

Results: The viability and migration of ARPE-19 cells were significantly decreased in the presence of 75 mmol/L as compared to 5.5 mmol/L glucose. The percentage of TUNEL-positive cells was significantly increased and the proliferative potential was decreased with 75 mmol/L compared to 5.5 mmol/L glucose. There were no significant differences in the results between 25 mmol/L and 5.5 mmol/L glucose. In the presence of 75 mmol/L glucose, the groups treated with anti-VEGF showed decreased cell viability and proliferation and increased apoptosis. However, there were no significant differences between the anti-VEGF groups.

Conclusion: High glucose level decreases the viability, wound healing ability, and proliferation of RPE cells, while increasing apoptosis. Furthermore, anti-VEGF agents interfered with the physiological functions of RPE cells under high-glucose conditions, accompanied by decreases in cell viability and proliferation.

Citing Articles

The Efficacy of Single-Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: Real-Life Results.

Simsek M, Citirik M, Ozates S, Tekin K, Ozkoyuncu D Beyoglu Eye J. 2022; 5(1):43-48.

PMID: 35098061 PMC: 8784452. DOI: 10.14744/bej.2020.06977.

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.

Merz P, Rockel N, Ballikaya S, Auffarth G, Schmack I BMC Ophthalmol. 2018; 18(1):316.

PMID: 30537942 PMC: 6288953. DOI: 10.1186/s12886-018-0978-9.

Essential Role of mTOR Signaling in Human Retinal Pigment Epithelial Cell Regeneration After Laser Photocoagulation.

Madrakhimov S, Yang J, Park H, Park T Lasers Med Sci. 2018; 34(5):1019-1029.

PMID: 30499005 DOI: 10.1007/s10103-018-2692-5.

Kinsenoside Ameliorates Oxidative Stress-Induced RPE Cell Apoptosis and Inhibits Angiogenesis via Erk/p38/NF-κB/VEGF Signaling.

Luo X, Gu S, Zhang Y, Zhang J Front Pharmacol. 2018; 9:240.

PMID: 29615910 PMC: 5870051. DOI: 10.3389/fphar.2018.00240.

References

Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt K, Szurman P . Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol. 2013; 97(7):917-23. DOI: 10.1136/bjophthalmol-2013-303130. View

Miura Y, Klettner A, Roider J . VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione. Invest Ophthalmol Vis Sci. 2010; 51(9):4848-55. DOI: 10.1167/iovs.09-4699. View

Treumer F, Klettner A, Baltz J, Hussain A, Miura Y, Brinkmann R . Vectorial release of matrix metalloproteinases (MMPs) from porcine RPE-choroid explants following selective retina therapy (SRT): towards slowing the macular ageing process. Exp Eye Res. 2012; 97(1):63-72. DOI: 10.1016/j.exer.2012.02.011. View

Klettner A, Mohle F, Roider J . Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol. 2010; 248(6):819-24. DOI: 10.1007/s00417-010-1317-x. View

Klettner A, Tahmaz N, Dithmer M, Richert E, Roider J . Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014; 98(10):1448-52. DOI: 10.1136/bjophthalmol-2014-305105. View

Cai L, Li W, Wang G, Guo L, Jiang Y, Kang Y . Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 2002; 51(6):1938-48. DOI: 10.2337/diabetes.51.6.1938. View

Klein R, Klein B, Moss S, Davis M, DeMets D . The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984; 91(12):1464-74. DOI: 10.1016/s0161-6420(84)34102-1. View

Nguyen Q, Brown D, Marcus D, Boyer D, Patel S, Feiner L . Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789-801. DOI: 10.1016/j.ophtha.2011.12.039. View

Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N . Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond). 2002; 16(2):163-70. DOI: 10.1038/sj.eye.6700095. View

10.

Thaler S, Fiedorowicz M, Choragiewicz T, Bolz S, Tura A, Henke-Fahle S . Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Ophthalmol. 2010; 88(5):e170-6. DOI: 10.1111/j.1755-3768.2010.01927.x. View

11.

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

12.

Nicholson B, Schachat A . A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010; 248(7):915-30. DOI: 10.1007/s00417-010-1315-z. View

13.

Spitzer M, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B . Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007; 245(12):1837-42. DOI: 10.1007/s00417-007-0568-7. View

14.

Moss S, Klein R, Klein B . The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6):998-1003. DOI: 10.1016/S0161-6420(98)96025-0. View

15.

Elman M, Qin H, Aiello L, Beck R, Bressler N, Ferris 3rd F . Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012; 119(11):2312-8. PMC: 3490003. DOI: 10.1016/j.ophtha.2012.08.022. View

16.

Peng S, Adelman R, Rizzolo L . Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions. Invest Ophthalmol Vis Sci. 2010; 51(6):3216-25. PMC: 2891474. DOI: 10.1167/iovs.09-4162. View

17.

Ho A, Scott I, Kim S, Brown G, Brown M, Ip M . Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology. 2012; 119(10):2179-88. DOI: 10.1016/j.ophtha.2012.07.058. View

18.

Chen Y, Chou H, Lin S, Chen Y, Lo Y, Chan H . Effect of high glucose on secreted proteome in cultured retinal pigmented epithelium cells: its possible relevance to clinical diabetic retinopathy. J Proteomics. 2012; 77:111-28. DOI: 10.1016/j.jprot.2012.07.014. View

19.

Rosenfeld P, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2010; 118(3):523-30. DOI: 10.1016/j.ophtha.2010.07.011. View

20.

Ammar D, Mandava N, Kahook M . The effects of aflibercept on the viability and metabolism of ocular cells in vitro. Retina. 2012; 33(5):1056-61. DOI: 10.1097/IAE.0b013e31827b646d. View